Rheumatoid arthritis depression associated with

Another TNFa monoclonal antibody known as etanercept (a fusion protein of human IgG and two p75 TNF receptors) [98] that is a competitive inhibitor of TNF s cell-surface receptor has been developed. Clinical studies have shown that etanercept therapy results in significant clinical benefits and is well tolerated and safe for long-term use [99-101]. Etanercept is given subcutaneously (25 mg) twice weekly for the treatment of rheumatoid arthritis [98]. It is also used in the treatment of psoriatic arthritis, and a recent clinical trial has reported that in addition to decreasing joint pain and fatigue, etanercept also decreases symptoms of depression associated with this chronic disease [102]. 

Panayi GS, Mills MM. Second-line drug treatment in rheumatoid arthritis associated with depressed autologous mixed lymphocyte reaction. Rheumatol Int 1986 6(l) 25-9. 

Many of the chronic conditions — cardiovascular disease, diabetes, cancer, obesity, autoimmune diseases, rheumatoid arthritis, asthma, and depression — are associated with increased production of thromboxane Aj (TXAj), leukotriene 84 (LTB4), II ip, lL-6, tumor necrosis factor (TNF), and C-reactive protein. All these factors increase by increases in omega-6 fatty acid intake and decrease by increases in omega-3 fatty acid intake, either ALA or EPA and DHA. EPA and DHA are more potent, and most studies have been carried out using EPA and DHA. 

---